[Corrections] Correction to Lancet Oncol 2017; 18: 1089 –103

Tap WD, Papai Z, Van Tine BA, et al. Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2017; 18: 1089 –103—the affiliation of Giovanni Grignani was incorrect and should have been “Candiolo Cancer Institute, FPO, IRCCS, Turin, Italy”. This correction has been made to the online version as of Jan 31, 2018.
Source: The Lancet Oncology - Category: Cancer & Oncology Tags: Corrections Source Type: research